C2019-31 – A peptoid-peptide hybrid, NMEG-aCGRP, and its use in cardiovascular diseases

Technology / 19-31: A peptoid-peptide hybrid, NMEG-aCGRP, and its use in cardiovascular diseases Inventor: Shannon Servoss, Jay Potts, Ambrish Kumar, Donald Dipette Status This invention is available for licensing General Description In an effort to save the lives of millions of people suffering from various cardiovascular diseases (CVD), researchers at the University of Arkansas have developed a novel vasodilator called 2-methoxyethyl glycine (NMEG)-calcitonin gene-related peptide (aCGRP) that could help treat conditions like heart attack, heart failure, high blood pressure, hypertension, and other cardiovascular diseases. The advancement of this technology could improve the traditional methods used to treat heart failure. NMEG-aCGRP promises to be one of the most robust vasodilators with enhanced stability and performance to treat CVD. It eliminates the drawback posed by the short half-life of aCGRP in the human serum. NMEG-aCGRP has proven to be more stable with experiments done on mice models and has been demonstrated to exhibit extended resistance to degradation while retaining identical biological activity of the original molecule. NMEG-aCGRP capitalizes on the crucial need to develop new therapies to treat longstanding CVD. Technology Ventures ventures@uark.edu 479-575-7243

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More